NASDAQ:CSTL - Castle Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.80
  • Forecasted Upside: 17.54 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$44.92
▼ -2.23 (-4.73%)
1 month | 3 months | 12 months
Get New Castle Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSTL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$52.80
▲ +17.54% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $52.80, with a high forecast of $70.00 and a low forecast of $35.00. The average price target represents a 17.54% upside from the last price of $44.92.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Castle Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020KeyCorpInitiated CoverageOverweight$70.00High
i
10/13/2020Canaccord GenuityBoost Price TargetBuy$52.00 ➝ $61.00Low
i
9/25/2020SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $57.00Low
i
9/3/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$47.00 ➝ $52.00Medium
i
Rating by Max Masucci at Canaccord Genuity
8/11/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $50.00High
i
5/21/2020Canaccord GenuityBoost Price TargetBuy$41.00 ➝ $47.00Low
i
Rating by Max Masucci at Canaccord Genuity
5/12/2020SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $45.00High
i
4/24/2020Canaccord GenuityReiterated RatingBuy$41.00Low
i
Rating by Max Masucci at Canaccord Genuity
3/27/2020Robert W. BairdLower Price TargetOutperform$38.00 ➝ $35.00Medium
i
3/26/2020Canaccord GenuityReiterated RatingBuy$41.00Low
i
Rating by Max Masucci at Canaccord Genuity
3/11/2020BTIG ResearchBoost Price Target$32.00 ➝ $41.00High
i
3/11/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $40.00High
i
3/11/2020Robert W. BairdBoost Price TargetOutperform$37.00 ➝ $38.00High
i
3/10/2020Canaccord GenuityInitiated CoverageBuy$38.00 ➝ $41.00High
i
Rating by Max Masucci at Canaccord Genuity
12/27/2019Canaccord GenuityBoost Price TargetBuy$34.00 ➝ $35.00High
i
Rating by Mark Massaro at Canaccord Genuity
9/4/2019SVB LeerinkSet Price TargetBuy$33.00Low
i
Rating by Puneet Souda at SVB Leerink LLC
9/4/2019Robert W. BairdBoost Price TargetOutperform$27.00 ➝ $31.00High
i
9/4/2019BTIG ResearchBoost Price TargetBuy$32.00High
i
9/4/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$26.00 ➝ $34.00High
i
8/19/2019BTIG ResearchInitiated CoverageBuy$25.00High
i
8/19/2019SVB LeerinkInitiated CoverageOutperform$28.00High
i
Rating by P. Souda at SVB Leerink LLC
8/19/2019Robert W. BairdInitiated CoverageOutperform$27.00High
i
8/19/2019Canaccord GenuityInitiated CoverageBuy$26.00High
i
(Data available from 11/25/2015 forward)
Castle Biosciences logo
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $44.92
$44.77
$47.15

50 Day Range

MA: $50.44
$46.21
$54.86

52 Week Range

Now: $44.92
$21.01
$55.31

Volume

142,151 shs

Average Volume

181,059 shs

Market Capitalization

$894.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51